APPLICATION
ANDA078152
TYPE
ANDA
ORIGINAL APPROVAL
2007-06-27
LATEST ACTION
2025-09-09
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Prescription
Products
ONDANSETRONPrescription
ONDANSETRON 4MG · TABLET, ORALLY DISINTEGRATING · ORAL
ONDANSETRONPrescription
ONDANSETRON 8MG · TABLET, ORALLY DISINTEGRATING · ORAL
Approval history
2025-09-09Labeling · Supplement 22 · standardAP
2018-02-13Labeling · Supplement 14 · standardAP
2017-03-30Labeling · Supplement 12 · standardAP
2014-12-08Labeling · Supplement 8 · standardAP
2014-12-08Labeling · Supplement 10 · standardAP
2011-09-30Labeling · Supplement 5AP
2011-09-30Labeling · Supplement 4AP
2011-07-25Labeling · Supplement 3AP
2008-10-23Labeling · Supplement 2AP
2008-08-18Labeling · Supplement 1AP
2007-06-27OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.